{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:43:55Z","timestamp":1793335435189,"version":"4.5.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.clinthera.2011.06.007","type":"journal-article","created":{"date-parts":[[2011,7,8]],"date-time":"2011-07-08T23:44:03Z","timestamp":1310168643000},"page":"812-827","source":"Crossref","is-referenced-by-count":55,"title":["Rifaximin: New Therapeutic Indication and Future Directions"],"prefix":"10.1016","volume":"33","author":[{"given":"Anastasia","family":"Rivkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanna","family":"Gim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2011.06.007_bib1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000089776","article-title":"Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic","volume":"73","author":"Scarpignato","year":"2006","journal-title":"Digestion"},{"key":"10.1016\/j.clinthera.2011.06.007_bib2","first-page":"51","article-title":"Pharmacokinetic study of rifaximin after oral administration in healthy volunteers","volume":"16","author":"Descombe","year":"1994","journal-title":"Int J Clin Pharmacol Res"},{"key":"10.1016\/j.clinthera.2011.06.007_bib3","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","article-title":"Rifaximin treatment in hepatic encephalopathy","volume":"362","author":"Bass","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2011.06.007_bib4","series-title":"Xifaxan (rifaximin) tablets [package insert]","year":"2010"},{"key":"10.1016\/j.clinthera.2011.06.007_bib6","first-page":"483","article-title":"In vitro antibacterial activity of rifaximin against Clostridium difficile, Campilobacter jejunii and Yersinia spp","volume":"13","author":"Ripa","year":"1987","journal-title":"Drugs Exp Clin Res"},{"key":"10.1016\/j.clinthera.2011.06.007_bib7","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/BF01982198","article-title":"In vitro activity of rifaximin against Helicobacter pylori","volume":"13","author":"Megraud","year":"1994","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.clinthera.2011.06.007_bib8","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1179\/joc.1999.11.5.391","article-title":"Intestinal protozoa in HIV-infected patients: effect of rifaximin in Cryptosporidium parvum and Blastocystis hominis infections","volume":"11","author":"Amenta","year":"1999","journal-title":"J Chemother"},{"key":"10.1016\/j.clinthera.2011.06.007_bib9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2165\/00003495-199549030-00009","article-title":"Rifaximin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria","volume":"49","author":"Gillis","year":"1995","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2011.06.007_bib10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000081991","article-title":"Rifaximin: in vitro and in vivo antibacterial activity\u2013a review","volume":"51","author":"Jiang","year":"2005","journal-title":"Chemotherapy"},{"key":"10.1016\/j.clinthera.2011.06.007_bib11","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1128\/AAC.44.8.2205-2206.2000","article-title":"In vitro activity and fecal concentration of rifaximin after oral administration","volume":"44","author":"Jiang","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2011.06.007_bib12","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/1120009X.1990.11739007","article-title":"Drug resistance in tuberculosis","volume":"2","author":"al-Orainey","year":"1990","journal-title":"J Chemother"},{"key":"10.1016\/j.clinthera.2011.06.007_bib13","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1126\/science.8153626","article-title":"Resistance to antibiotics mediated by target alterations","volume":"264","author":"Spratt","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2011.06.007_bib14","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000007297","article-title":"In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species","volume":"46","author":"Marchese","year":"2000","journal-title":"Chemotherapy"},{"key":"10.1016\/j.clinthera.2011.06.007_bib15","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0732-8893(93)90004-Q","article-title":"Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative","volume":"16","author":"Hoover","year":"1993","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.clinthera.2011.06.007_bib16","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/j.1469-0691.2004.00997.x","article-title":"Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci","volume":"10","author":"DuPont","year":"2004","journal-title":"Clin Microbiol Inf"},{"key":"10.1016\/j.clinthera.2011.06.007_bib17","first-page":"979","article-title":"Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin","volume":"12","author":"De Leo","year":"1986","journal-title":"Drugs Exp Clin Res"},{"key":"10.1016\/j.clinthera.2011.06.007_bib18","first-page":"387","article-title":"A non-absorbable rifamycin for treatment of hepatic encephalopathy","volume":"11","author":"Testa","year":"1985","journal-title":"Drugs Exp Clin Res"},{"key":"10.1016\/j.clinthera.2011.06.007_bib20","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1345\/aph.1H395","article-title":"Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol\/norgestimate in healthy females","volume":"41","author":"Trapnell","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2011.06.007_bib21","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1592\/phco.27.10.1361","article-title":"The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers","volume":"27","author":"Pentikis","year":"2007","journal-title":"Pharmacotherapy"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2011.06.007_bib22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1746-6342.2006.03215.x","article-title":"Review article: the burden of hepatic encephalopathy","volume":"25","author":"Poordad","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2011.06.007_bib23","series-title":"Pharmacotherapy Principles and Practice","first-page":"387","article-title":"Portal hypertension and cirrhosis","author":"Ryan","year":"2010"},{"key":"10.1016\/j.clinthera.2011.06.007_bib24","series-title":"Bockus Gastroenterology","first-page":"1998","article-title":"Hepatic encephalopathy","author":"Ferenci","year":"1995"},{"key":"10.1016\/j.clinthera.2011.06.007_bib25","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0168-8278(99)80144-5","article-title":"Prognostic significance of hepatic encephalopathy in patients with cirrhosis","volume":"30","author":"Bustamante","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinthera.2011.06.007_bib26","first-page":"617","article-title":"Current trends in the treatment of hepatic encephalopathy","volume":"5","author":"Al Sibae","year":"2009","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.clinthera.2011.06.007_bib27","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/lt.21129","article-title":"Hepatic encephalopathy as a predictor of survival in patients with end\u2212stage liver disease","volume":"13","author":"Stewart","year":"2007","journal-title":"Liver Transpl"},{"key":"10.1016\/j.clinthera.2011.06.007_bib28","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1023\/B:MEBR.0000043979.58915.41","article-title":"Pathophysiology of hepatic encephalopathy: a new look at GABA from the molecular standpoint","volume":"19","author":"Ahboucha","year":"2004","journal-title":"Metab Brain Dis"},{"key":"10.1016\/j.clinthera.2011.06.007_bib29","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1111\/j.1572-0241.2001.03964.x","article-title":"Hepatic encephalopathy","volume":"96","author":"Blei","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2011.06.007_bib30","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2036.2009.04211.x","article-title":"Review article: the modern management of hepatic encephalopathy","volume":"31","author":"Bajaj","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2011.06.007_bib31","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/hep.21533","article-title":"Lactulose improves cognitive function and health-related quality of life in cirrhotic patients with minimal hepatic encephalopathy","volume":"45","author":"Prasad","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2011.06.007_bib32","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/MEG.0b013e3282f3e6f5","article-title":"An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy","volume":"20","author":"Sharma","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2011.06.007_bib33","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1053\/j.gastro.2009.05.056","article-title":"Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo","volume":"137","author":"Sharma","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2011.06.007_bib34","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000081994","article-title":"Management of hepatic encephalopathy: role of rifaximin","volume":"51","author":"Zeneroli","year":"2005","journal-title":"Chemotherapy"},{"key":"10.1016\/j.clinthera.2011.06.007_bib35","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s10620-006-9442-4","article-title":"Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy","volume":"52","author":"Leevy","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.clinthera.2011.06.007_bib36","author":"Wolf"},{"key":"10.1016\/j.clinthera.2011.06.007_bib38","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1592\/phco.28.8.1019","article-title":"Rifaximin for the treatment of hepatic encephalopathy","volume":"28","author":"Lawrence","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2011.06.007_bib39","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1345\/aph.1K436","article-title":"Rifaximin for treatment of hepatic encephalopathy","volume":"43","author":"Maclayton","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2011.06.007_bib40","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0016-5085(77)80135-2","article-title":"Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy","volume":"72","author":"Conn","year":"1977","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2011.06.007_bib41","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1053\/jlts.2002.31340","article-title":"Model for end-stage liver disease and Child-Turcotte-Pugh score as predictors of pretransplantation disease severity, posttransplantation outcome, and resource utilization in United Network for Organ Sharing status 2A patients","volume":"8","author":"Brown","year":"2002","journal-title":"Liver Transpl"},{"key":"10.1016\/j.clinthera.2011.06.007_bib42","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/ajg.2008.122","article-title":"American College of Gastroenterology Task Force on Irritable Bowel Syndrome","volume":"104","author":"Brandt","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2011.06.007_bib43","doi-asserted-by":"crossref","first-page":"A-545","DOI":"10.1016\/S0016-5085(08)62544-5","article-title":"Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short term treatment leading to long term sustained response","volume":"134","author":"Lembo","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2011.06.007_bib44","doi-asserted-by":"crossref","first-page":"557","DOI":"10.7326\/0003-4819-145-8-200610170-00004","article-title":"The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome","volume":"145","author":"Pimentel","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2011.06.007_bib45","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1572-0241.2006.00458.x","article-title":"A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence","volume":"101","author":"Sharara","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2011.06.007_bib46","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10620-007-9839-8","article-title":"Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS","volume":"53","author":"Yang","year":"2008","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.clinthera.2011.06.007_bib47","first-page":"412","article-title":"Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study","volume":"98","author":"Pimentel","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2011.06.007_bib48","doi-asserted-by":"crossref","first-page":"475i","DOI":"10.1016\/S0016-5085(10)60292-2","article-title":"Rifaximin treatment for 2 weeks provides acute and sustained relief over 12 weeks of IBS symptoms in non-constipated irritable bowel syndrome: results from 2 North American Phase 3 trials (Target 1 and Target 2)","volume":"138","author":"Pimentel","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2011.06.007_bib49","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1004409","article-title":"Rifaximin therapy for patients with irritable bowel syndrome without constipation","volume":"364","author":"Pimentel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2011.06.007_bib50","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1086\/651706","article-title":"Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)","volume":"31","author":"Cohen","year":"2010","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.clinthera.2011.06.007_bib51","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/clind\/15.4.573","article-title":"Antibiotic-associated diarrhea","volume":"15","author":"Bartlett","year":"1992","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2011.06.007_bib52","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/clinids\/6.Supplement_1.S235","article-title":"Treatment of antibiotic-associated pseudomembranous colitis","volume":"6","author":"Bartlett","year":"1984","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.clinthera.2011.06.007_bib53","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1086\/646934","article-title":"Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991","volume":"15","author":"Olson","year":"1994","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.clinthera.2011.06.007_bib54","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/infdis\/159.2.340","article-title":"Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism","volume":"159","author":"Johnson","year":"1989","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clinthera.2011.06.007_bib55","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1128\/JCM.38.6.2386-2388.2000","article-title":"Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea","volume":"38","author":"Barbut","year":"2000","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.clinthera.2011.06.007_bib56","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1086\/430311","article-title":"Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole","volume":"40","author":"Musher","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2011.06.007_bib57","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1086\/496986","article-title":"Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec","volume":"41","author":"Pepin","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2011.06.007_bib58","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1128\/AAC.01623-06","article-title":"In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004","volume":"51","author":"Hecht","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2011.06.007_bib59","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/MCG.0b013e31814a4e97","article-title":"Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study","volume":"43","author":"Garey","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.clinthera.2011.06.007_bib60","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/1756283X10372985","article-title":"Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial","volume":"3","author":"Basu","year":"2010","journal-title":"Ther Adv Gastroenterol"},{"key":"10.1016\/j.clinthera.2011.06.007_bib61","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1086\/511870","article-title":"Interruption of recurrent Clostridium difficile\u2013associated diarrhea episodes by serial therapy with vancomycin and rifaximin","volume":"44","author":"Johnson","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2011.06.007_bib62","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.anaerobe.2009.08.004","article-title":"Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment","volume":"15","author":"Johnson","year":"2009","journal-title":"Anaerobe"},{"key":"10.1016\/j.clinthera.2011.06.007_bib63","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/lt.22092","article-title":"Rifaximin for the treatment of recurrent Clostridium difficile infection after liver transplantation: a case series","volume":"16","author":"Neff","year":"2010","journal-title":"Liver Transpl"},{"key":"10.1016\/j.clinthera.2011.06.007_bib64","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1097\/01.mcg.0000225685.37465.e7","article-title":"Efficacy of rifaximin and vancomycin combination therapy in a patient with refractory Clostridium difficile-associated diarrhea","volume":"41","author":"Berman","year":"2007","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.clinthera.2011.06.007_bib65","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1128\/AAC.00342-08","article-title":"Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile","volume":"52","author":"O'Connor","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2011.06.007_bib66","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1086\/596315","article-title":"High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital","volume":"48","author":"Curry","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2011.06.007_bib67","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/S0168-8278(09)60209-9","article-title":"Safety of rifaximin in patients with hepatic encephalopathy: results of a randomized, phase 3, placebo-controlled clinical trial","volume":"50","author":"Mullen","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinthera.2011.06.007_bib68","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1016\/j.transproceed.2006.10.107","article-title":"Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy","volume":"38","author":"Neff","year":"2006","journal-title":"Transplant Proc"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291811004036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291811004036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,21]],"date-time":"2020-06-21T06:24:28Z","timestamp":1592720668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291811004036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":65,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0149291811004036"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2011.06.007","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}